Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan 15;48(1):64-153.

The Black Book of Psychotropic Dosing and Monitoring

Alan F Schatzberg  1 , DeBattista Charles  1
Affiliations
Review

The Black Book of Psychotropic Dosing and Monitoring

Alan F Schatzberg et al. Psychopharmacol Bull. .
No abstract available

PubMed Disclaimer

Similar articles

See all similar articles

References

Antidepressants

    1. Agosti V, Stewart JW, Quitkin FM. Life satisfaction and psychosocial functioning in chronic depression: effect of acute treatment with antidepressants. J Affect Disord. 1991;23(1):35–41. 1774421. - PubMed
    1. Aguglia E, Casacchia M, Cassano GB et al. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol. 1993;8(3):197–202. 8263318. - PubMed
    1. Aizenberg D, Zemishlany Z, Weizman A. Cyproheptadine treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin Neuropharmacol. 1995;18(4):320–324. 8665544. - PubMed
    1. Alam MY, Jacobsen PL, Chen Y et al. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol. 2014;29(1):36–44. 24169027. - PMC - PubMed
    1. Altamura AC, Pioli R, Vitto M, Mannu P. Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders. Int Clin Psychopharmacol. 1999;14(4):239–245. 10468317. - PubMed

Mood Stabilizers

    1. Abou-Saleh MT. Who responds to prophylactic lithium therapy? Br J Psychiatry. 1993;(21) Suppl:20–26. 8217063. - PubMed
    1. Abraham G, Delva N, Waldron J et al. Lithium treatment: a comparison of once- and twice-daily dosing. Acta Psychiatr Scand. 1992;85(1):65–69. 1546552. - PubMed
    1. Altesman R, Cole JO. Lithium therapy: a practical review, in Psychopharmacology Update. In: Cole JO, editor. Lexington, MA: Collamore Press; 1980. pp. 3–18.
    1. Altshuler LL, Suppes T, Black DO et al. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry. 2006;163(2):313–315. 16449487. - PubMed
    1. Altshuler LL, Post RM, Hellemann G et al. Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study. J Clin Psychiatry. 2009;70(4):450–457. 19358785. - PubMed

Antipsychotics

    1. Adler LA, Peselow E, Rotrosen J et al. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry. 1993;150(9):1405–1407. 8102511. - PubMed
    1. Allison DB, Mentore JL, Heo M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686–1696. 10553730. - PubMed
    1. Alvir JM, Lieberman JA, Safferman AZ et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med. 1993;329(3):162–167. 8515788. - PubMed
    1. Aman MG, Arnold LE, McDougle CJ et al. Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol. 2005;15(6):869–884. 16379507. - PubMed
    1. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596–601. 14747245. - PubMed

Anxiolytics

    1. Ahearn EP, Juergens T, Cordes T et al. A review of atypical antipsychotic medications for posttraumatic stress disorder. Int Clin Psychopharmacol. 2011;26(4):193–200. 21597381. - PubMed
    1. Alao A, Selvarajah J, Razi S. The use of clonidine in the treatment of nightmares among patients with co-morbid PTSD and traumatic brain injury. Int J Psychiatry Med. 2012;44(2):165–169. 23413663. - PubMed
    1. American Psychiatric Association. 3rd. Washington, DC: American Psychiatric Association; 1987. Diagnostic and Statistical Manual of Mental Disorders. Revised.
    1. American Psychiatric Association. 4th. Washington, DC: American Psychiatric Association; 1994. Diagnostic and Statistical Manual of Mental Disorders.
    1. American Psychiatric Association. 4th. Washington, DC: American Psychiatric Association; 2000. Diagnostic and Statistical Manual of Mental Disorders.

Hypnotics

    1. Backonja M, Beydoun A, Edwards KR et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280(21):1831–1836. 9846777. - PubMed
    1. Bajor LA, Ticlea AN, Osser DN. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on posttraumatic stress disorder. Harv Rev Psychiatry. 2011;19(5):240–258. 21916826. - PubMed
    1. Bunney WE, Jr, Azarnoff DL, Brown BW, Jr et al. Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion. Arch Gen Psychiatry. 1999;56(4):349–352. 10197830. - PubMed
    1. Buysse DJ, Dorsey CM. Current and experimental therapeutics of insomnia, in American College of Neuro-Psychopharmacology: 1A Fifth Generation of Progress. In: Davis JM, Charney D, Coyle J, editors. Philadelphia, PA: Lippincott Williams & Wilkins; 2002. pp. 1931–1943.
    1. Camargos EF, Louzada LL, Quintas JL et al. Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study (Epub ahead of print) Am J Geriatr Psychiatry. 2014 Jan;4 24495406. - PubMed

Stimulants

    1. Angrist B, Rotrosen J, Gershon S. Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects. Psychopharmacology (Berl) 1980;67(1):31–38. 6102776. - PubMed
    1. Angrist B, Peselow E, Rubinstein M et al. Amphetamine response and relapse risk after depot neuroleptic discontinuation. Psychopharmacology (Berl) 1985;85(3):277–283. 2860683. - PubMed
    1. August GJ, Raz N, Papanicolaou AC et al. Fenfluramine treatment in infantile autism: neurochemical, electrophysiological, and behavioral effects. J Nerv Ment Dis. 1984;172(10):604–612. 6384430. - PubMed
    1. Biederman G. Fenfluramine (Pondimin) in autism. Biological Therapies in Psychiatry Newsletter. 1985;8:25–28.
    1. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005;366(9481):237–248. 16023516. - PubMed

Substance Use Disorders

    1. Arndt IO, Dorozynsky L, Woody GE et al. Desipramine treatment of cocaine dependence in methadone-maintained patients. Arch Gen Psychiatry. 1992;49(11):888–893. 1444727. - PubMed
    1. Arndt IO, McLellan AT, Dorozynsky L et al. Desipramine treatment for cocaine dependence. Role of antisocial personality disorder. J Nerv Ment Dis. 1994;182(3):151–156. 8113775. - PubMed
    1. American Society of Health-System Pharmacists. Besthesda, MD: ASHP; 2003. AHFS Drug Information 2003.
    1. Bagasra O, Forman LJ, Howeedy A, Whittle P. A potential vaccine for cocaine abuse prophylaxis (also see comments) Immunopharmacology. 1992;23(3):173–179. 1500284. - PubMed
    1. Batki SL, Manfredi LB, Jacob P, 3rd, Jones RT. Fluoxetine for cocaine dependence in methadone maintenance: quantitative plasma and urine cocaine/benzoylecgonine concentrations. J Clin Psychopharmacol. 1993;13(4):243–250. 8376611. - PubMed

Agents for Cognitive Disorders

    1. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer’s disease: implications for therapy. Am J Psychiatry. 1994;151(8):1105–1113. 7518651. - PubMed
    1. Bartus RT, Dean RL, 3rd, Beer B et al. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217(4558):408–414. 7046051. - PubMed
    1. Behl C. Vitamin E and other antioxidants in neuroprotection. Int J Vitam Nutr Res. 1999;69(3):213–219. 10389030. - PubMed
    1. Behl C, Davis J, Cole GM et al. Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem Biophys Res Commun. 1992;186(2):944–950. 1497677. - PubMed
    1. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD005593. 16437532. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources